BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10460750)

  • 1. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis.
    Matsumoto Y; Horiba K; Usuki J; Chu SC; Ferrans VJ; Moss J
    Am J Respir Cell Mol Biol; 1999 Sep; 21(3):327-36. PubMed ID: 10460750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis.
    Zhe X; Schuger L
    J Histochem Cytochem; 2004 Dec; 52(12):1537-42. PubMed ID: 15557209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.
    Klarquist J; Barfuss A; Kandala S; Reust MJ; Braun RK; Hu J; Dilling DF; McKee MD; Boissy RE; Love RB; Nishimura MI; Le Poole IC
    Am J Pathol; 2009 Dec; 175(6):2463-72. PubMed ID: 19893037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis.
    Gilbert ER; Eby JM; Hammer AM; Klarquist J; Christensen DG; Barfuss AJ; Boissy RE; Picken MM; Love RB; Dilling DF; Le Poole IC
    Am J Pathol; 2013 Jul; 183(1):226-34. PubMed ID: 23665200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis.
    Matsui K; Takeda K; Yu ZX; Travis WD; Moss J; Ferrans VJ
    Arch Pathol Lab Med; 2000 Feb; 124(2):267-75. PubMed ID: 10656737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis.
    Evans SE; Colby TV; Ryu JH; Limper AH
    Chest; 2004 Mar; 125(3):1063-70. PubMed ID: 15006970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status.
    Usuki J; Horiba K; Chu SC; Moss J; Ferrans VJ
    Arch Pathol Lab Med; 1998 Oct; 122(10):895-902. PubMed ID: 9786350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of human telomerase reverse transcriptase in lymphangioleiomyomatosis.
    Kumaki F; Takeda K; Yu ZX; Moss J; Ferrans VJ
    Am J Respir Crit Care Med; 2002 Jul; 166(2):187-91. PubMed ID: 12119231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features.
    Ferrans VJ; Yu ZX; Nelson WK; Valencia JC; Tatsuguchi A; Avila NA; Riemenschn W; Matsui K; Travis WD; Moss J
    J Nippon Med Sch; 2000 Oct; 67(5):311-29. PubMed ID: 11031360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor.
    Fetsch PA; Fetsch JF; Marincola FM; Travis W; Batts KP; Abati A
    Mod Pathol; 1998 Aug; 11(8):699-703. PubMed ID: 9720495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax.
    Tanaka H; Imada A; Morikawa T; Shibusa T; Satoh M; Sekine K; Abe S
    Eur Respir J; 1995 Nov; 8(11):1879-82. PubMed ID: 8620956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.
    Dilling DF; Gilbert ER; Picken MM; Eby JM; Love RB; Le Poole IC
    Am J Respir Cell Mol Biol; 2012 Jan; 46(1):1-5. PubMed ID: 21940815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanosomal targeting sequences from gp100 are essential for MHC class II-restricted endogenous epitope presentation and mobilization to endosomal compartments.
    Lepage S; Lapointe R
    Cancer Res; 2006 Feb; 66(4):2423-32. PubMed ID: 16489049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.
    Valencia JC; Steagall WK; Zhang Y; Fetsch P; Abati A; Tsukada K; Billings E; Hearing VJ; Yu ZX; Pacheco-Rodriguez G; Moss J
    Chest; 2015 Mar; 147(3):771-777. PubMed ID: 25411763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma.
    Clements D; Markwick LJ; Puri N; Johnson SR
    J Immunol; 2010 Aug; 185(3):1812-21. PubMed ID: 20585037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin K is Superior to HMB45 for the Diagnosis of Pulmonary Lymphangioleiomyomatosis.
    Rolim I; Makupson M; Lovrenski A; Farver C
    Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):108-112. PubMed ID: 34433182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and ultrastructural localization of HMB-45 antigen.
    Kikuchi A; Shimizu H; Nishikawa T
    Br J Dermatol; 1996 Sep; 135(3):400-5. PubMed ID: 8949433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mouse monoclonal antibody (FKH1) detecting human melanoma-associated antigens: production, partial characterization and immunohistochemical analysis].
    Fukaya T
    Hokkaido Igaku Zasshi; 1991 May; 66(3):300-10. PubMed ID: 1885156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients.
    Hayashi T; Kumasaka T; Mitani K; Terao Y; Watanabe M; Oide T; Nakatani Y; Hebisawa A; Konno R; Takahashi K; Yao T; Seyama K
    Am J Surg Pathol; 2011 Dec; 35(12):1776-85. PubMed ID: 22020043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
    Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
    Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.